ARTICLE
27 March 2018

Patenting Antibodies: Obviousness Considerations

FH
Finnegan, Henderson, Farabow, Garrett & Dunner, LLP

Contributor

Finnegan, Henderson, Farabow, Garrett & Dunner, LLP is a law firm dedicated to advancing ideas, discoveries, and innovations that drive businesses around the world. From offices in the United States, Europe, and Asia, Finnegan works with leading innovators to protect, advocate, and leverage their most important intellectual property (IP) assets.
Under 35 U.S.C. § 103, a claim is not patentable if the "differences between the claimed invention and prior art are such that the claimed invention as a whole would have been obvious" to a person of ordinary skill...
United States Intellectual Property
To print this article, all you need is to be registered or login on Mondaq.com.

Under 35 U.S.C. § 103, a claim is not patentable if the "differences between the claimed invention and prior art are such that the claimed invention as a whole would have been obvious" to a person of ordinary skill in the art, before the effective filing date of the claimed invention.  The U.S. Supreme Court set forth half a century ago a four-prong test to determine obviousness: (i) the scope and content of prior art, (ii) differences between claimed subject matter and prior art, (iii) the level of ordinary skill in the art, and (iv) objective evidence of nonobviousness, such as long-felt but unsolved need, failure of others, commercial success, unexpected results, and skepticism.  Graham v. John Deere Co., 383 U.S. 1, 17–18 (1966).

Click here to read the full article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

ARTICLE
27 March 2018

Patenting Antibodies: Obviousness Considerations

United States Intellectual Property

Contributor

Finnegan, Henderson, Farabow, Garrett & Dunner, LLP is a law firm dedicated to advancing ideas, discoveries, and innovations that drive businesses around the world. From offices in the United States, Europe, and Asia, Finnegan works with leading innovators to protect, advocate, and leverage their most important intellectual property (IP) assets.
See More Popular Content From

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More